To address these clinically relevant issues and improve treatment outcomes of sporadic HNSCCs and in FA, we investigated stimulation of the cGAS/STING/IFN-1 pathway by therapy-relevant genotoxic challenges and concomitant impairment of the DDR. This evidence concerns the gene CGAS and Friedreich ataxia.